{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Inflammation+%28I%29", "query": { "intervention": "Inflammation (I)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 112, "total_pages": 12, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Inflammation+%28I%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T23:20:15.543Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00373360", "title": "Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Hypertension" ], "interventions": [ { "name": "treprostinil sodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "United Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 10, "start_date": "2006-09", "completion_date": "2008-01", "has_results": true, "last_update_posted_date": "2013-01-07", "last_synced_at": "2026-09-08T23:20:15.543Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00373360" }, { "nct_id": "NCT01468337", "title": "Topical Interferon Gamma-1b for Central Serous Chorioretinopathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Retinal Disease", "Macular Disease" ], "interventions": [ { "name": "Interferon gamma-1b", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Eye Institute (NEI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2011-10", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2024-01-30", "last_synced_at": "2026-09-08T23:20:15.543Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01468337" }, { "nct_id": "NCT02966665", "title": ": Vascular Function in Health and Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Obstructive Pulmonary Disease", "Pulmonary Artery Hypertension", "Heart Failure", "Hypertension" ], "interventions": [ { "name": "Maximum Exercise Tests", "type": "OTHER" }, { "name": "BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate", "type": "DRUG" }, { "name": "BQ-123", "type": "DRUG" }, { "name": "Fexofenadine, Ranitidine", "type": "DRUG" }, { "name": "Angiotensin-II, Valsartan", "type": "OTHER" }, { "name": "Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine", "type": "DRUG" }, { "name": "BQ-123, MitoQ, BH4", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Russell Richardson", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 420, "start_date": "2008-09", "completion_date": "2026-08", "has_results": false, "last_update_posted_date": "2025-09-26", "last_synced_at": "2026-09-08T23:20:15.543Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02966665" }, { "nct_id": "NCT06445192", "title": "Evaluating the Impact of a Virtually Supervised Exercise Intervention and Group Counseling on Inflammation and the Microbiome of Smokers at High Risk for Lung Cancer, BE FIT Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lung Carcinoma" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Exercise Counseling", "type": "OTHER" }, { "name": "Exercise Intervention", "type": "OTHER" }, { "name": "Medical Device Usage and Evaluation", "type": "OTHER" }, { "name": "Physical Performance Testing", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Telemedicine", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 65, "start_date": "2023-11-03", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-09-08T23:20:15.543Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06445192" }, { "nct_id": "NCT00031018", "title": "Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Memory Disorders", "Alzheimer's Disease" ], "interventions": [ { "name": "Aricept", "type": "DRUG" }, { "name": "IFN-alpha2A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Center for Research Resources (NCRR)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2008-02-05", "last_synced_at": "2026-09-08T23:20:15.543Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00031018" }, { "nct_id": "NCT04747912", "title": "Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoblastic Leukemia", "Acute Lymphoblastic Leukemia", "ph+ Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Inotuzumab ozogamicin", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Ponatinib", "type": "DRUG" }, { "name": "Purinethol (6-Mercaptopurine)", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-03-02", "completion_date": "2028-03-01", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-09-08T23:20:15.543Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04747912" }, { "nct_id": "NCT05641831", "title": "Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clonal Cytopenia of Undetermined Significance" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Canakinumab", "type": "DRUG" }, { "name": "Chest Radiography", "type": "PROCEDURE" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Uma Borate", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2023-02-06", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-01-02", "last_synced_at": "2026-09-08T23:20:15.543Z", "location_count": 6, "location_summary": "Miami, Florida • New York, New York • Columbus, Ohio + 2 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05641831" }, { "nct_id": "NCT02235051", "title": "Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer Survivor", "Estrogen Receptor-positive Breast Cancer", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer", "Postmenopausal" ], "interventions": [ { "name": "exercise intervention", "type": "BEHAVIORAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "quality-of-life assessment", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "56 Years", "maximum_age": null, "sex": "FEMALE", "summary": "56 Years and older · Female only" }, "enrollment_count": 50, "start_date": "2014-09-07", "completion_date": "2022-06-03", "has_results": false, "last_update_posted_date": "2023-03-21", "last_synced_at": "2026-09-08T23:20:15.543Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02235051" }, { "nct_id": "NCT02437253", "title": "Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mucopolysaccharidosis Type I", "Mucopolysaccharidosis Type II", "Mucopolysaccharidosis Type VI" ], "interventions": [ { "name": "Adalimumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": null, "sex": "ALL", "summary": "5 Years and older" }, "enrollment_count": 2, "start_date": "2015-05", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2017-09-15", "last_synced_at": "2026-09-08T23:20:15.543Z", "location_count": 1, "location_summary": "Torrance, California", "locations": [ { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02437253" }, { "nct_id": "NCT06508021", "title": "A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Fibrodysplasia Ossificans Progressiva" ], "interventions": [ { "name": "Andecaliximab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ashibio Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 92, "start_date": "2024-10-25", "completion_date": "2029-02-04", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-09-08T23:20:15.543Z", "location_count": 3, "location_summary": "San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06508021" } ] }